Zai Lab Ltd. ADR (ZLAB): Price and Financial Metrics
ZLAB Price/Volume Stats
| Current price | $14.99 | 52-week high | $39.50 |
| Prev. close | $14.07 | 52-week low | $13.48 |
| Day low | $14.48 | Volume | 455,400 |
| Day high | $15.27 | Avg. volume | 637,118 |
| 50-day MA | $17.76 | Dividend yield | N/A |
| 200-day MA | $23.90 | Market Cap | 1.49B |
ZLAB Stock Price Chart Interactive Chart >
Zai Lab Ltd. ADR (ZLAB) Company Bio
Zai Lab is an innovative, research-based, commercial stage biopharmaceutical company based in China and the U.S. focused on bringing transformative medicines for oncology, autoimmune disorders, infectious diseases and neurological disorders to patients in China and around the world. Our longer-term goal is to leverage our China-based competencies and resources to enable and impact human health worldwide. (Source:ZaiLaborator)
Latest ZLAB News From Around the Web
Below are the latest news stories about ZAI LAB LTD that investors may wish to consider to help them evaluate ZLAB as an investment opportunity.
What Makes Zai Lab Limited Unsponsored ADR (ZLAB) a New Buy StockZai Lab Limited Unsponsored ADR (ZLAB) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term. |
Zai Lab Announces Participation in January Investor ConferenceSHANGHAI & CAMBRIDGE, Mass., December 19, 2023--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that members of the Company’s senior management team will participate in the following investor conference in January 2024: |
Paratek Pharmaceuticals Announces Inclusion of Oral NUZYRA® in China’s National Reimbursement Drug ListBOSTON, Dec. 13, 2023 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc., a biopharmaceutical company focused on the development and commercialization of innovative therapies for life-threatening diseases and other public health threats, today announced that China’s National Healthcare Security Administration (NHSA) has added the oral formulation of NUZYRA® (omadacycline) to the country’s National Reimbursement Drug List (NRDL) for treatment of community-acquired bacterial pneumonia (CABP) and ac |
Zai Lab Announces the First Listing of VYVGART® (efgartigimod alfa injection) and Other Updates in China’s National Reimbursement Drug ListSHANGHAI & CAMBRIDGE, Mass., December 13, 2023--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that the 2023 National Reimbursement Drug List (NRDL) released by China’s National Healthcare Security Administration (NHSA) has been updated to include the following medicines and indications: |
Companies Like Zai Lab (NASDAQ:ZLAB) Are In A Position To Invest In GrowthThere's no doubt that money can be made by owning shares of unprofitable businesses. For example, although... |
ZLAB Price Returns
| 1-mo | -7.35% |
| 3-mo | -34.83% |
| 6-mo | -34.74% |
| 1-year | -58.26% |
| 3-year | -91.34% |
| 5-year | -47.24% |
| YTD | -45.15% |
| 2023 | -10.98% |
| 2022 | -51.15% |
| 2021 | -53.56% |
| 2020 | 225.41% |
| 2019 | 79.11% |
Loading social stream, please wait...